Wide Ranks

IRWD

Ironwood Pharmaceuticals, Inc.

3.67

Top Statistics
Market Cap 587 M Forward PE 15.13 Revenue Growth -19.50 %
Current Ratio 3.62 Trailing PE 0.0000 Earnings Growth -77.30 %
Profit Margins -0.65 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 11.44 Enterprise / Revenue 2.94 Price To Sales Trailing12 Months 1.55
Profitability
Profit Margins -0.65 % Operating Margins 28.01 %
Balance Sheet
Total Cash 88 M Total Cash Per Share 0.5510 Total Debt 614 M
Total Debt To Equity Current Ratio 3.62 Book Value Per Share -1.95
All Measures
Short Ratio 644.00 % Message Board Id finmb_31498 Fax 617 494 0480
Shares Short Prior Month 11 M City Boston Uuid bbecc65d-4c04-3cd5-be4a-aec950ecb433
Previous Close 3.52 First Trade Date Epoch Utc 1 B Book Value -1.95
Beta 0.4750 Total Debt 614 M Volume 1 M
Last Split Date 1 B Fifty Two Week Low 3.26 Total Cash Per Share 0.5510
Total Revenue 378 M Shares Short Previous Month Date 1 B Target Median Price 12.00
Audit Risk 6 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins 28.01 % Target Mean Price 12.50 Net Income To Common -2463000
Short Percent Of Float 0.1035 Implied Shares Outstanding 160 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 88 M Next Fiscal Year End 1 B Revenue Per Share 2.39
Held Percent Insiders 0.0168 Ebitda Margins 25.74 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 6
Regular Market Previous Close 3.52 Target Low Price 5.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 4.15 Open 3.52 Free Cashflow 79 M
State MA Dividend Yield 0.00 % Return On Assets 0.1305
Time Zone Short Name EST Board Risk 1 Trailing Eps -0.0100
Day Low 3.44 Address1 100 Summer Street Shares Outstanding 160 M
Compensation Risk 2 Price Hint 4 Target High Price 23.00
Website https://www.ironwoodpharma.com 52 Week Change -0.6293 Average Volume 1 M
Earnings Quarterly Growth -76.20 % Forward Eps 0.3800 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 332.90 % Last Split Factor 1194:1000
Regular Market Day High 3.71 Is_sp_500 False Profit Margins -0.65 %
Fifty Two Week High 15.70 Day High 3.71 Shares Short 8 M
Regular Market Open 3.52 Industry Key drug-manufacturers-specialty-generic Earnings Growth -77.30 %
Enterprise To Revenue 2.94 Revenue Growth -19.50 % Shares Percent Shares Out 0.0535
Operating Cashflow 124 M Currency USD Time Zone Full Name America/New_York
Market Cap 587 M Is_nasdaq_100 False Zip 02110
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Ironwood Pharmaceuticals, Inc.
Overall Risk 3 Regular Market Day Low 3.44 Held Percent Institutions 1.06
Current Price 3.67 Address2 Suite 2300 Enterprise To Ebitda 11.44
Financial Currency USD Current Ratio 3.62 Gross Margins 66.86 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 6 Country United States
Float Shares 132 M Two Hundred Day Average 6.50 Governance Epoch Date 1 B
Enterprise Value 1 B Price To Sales Trailing12 Months 1.55 Forward PE 15.13
Regular Market Volume 1 M Ebitda 97 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.

It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.

The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.

Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.